Clinical Trial Update: Open Label Extension Study of AMX0035 in Patients With ALS [Phase 2]

View source ↗

Summary

An open-label extension study of AMX0035 in Amyotrophic Lateral Sclerosis (ALS) completed Phase 2, with results from the extension reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• AMX0035 (sodium phenylbutyrate and tauroursodeoxycholic acid)

Snippet

Sponsor: Amylyx Pharmaceuticals Inc. | Conditions: Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Status: COMPLETED | Results posted: 2025-08-13